{
  "topic": "Mechanism of Action of Mycophenolate",
  "questions": [
    {
      "question": "What is the primary mechanism of action of mycophenolate?",
      "options": [
        "Inhibition of T-cell activation by blocking calcineurin",
        "Inhibition of inosine monophosphate dehydrogenase (IMPDH)",
        "Blockade of interleukin-2 (IL-2) receptors",
        "Inhibition of DNA gyrase"
      ],
      "answer": "Inhibition of inosine monophosphate dehydrogenase (IMPDH)"
    },
    {
      "question": "Which enzyme does mycophenolate specifically inhibit to exert its immunosuppressive effects?",
      "options": [
        "Dihydrofolate reductase",
        "Inosine monophosphate dehydrogenase (IMPDH)",
        "Calcineurin",
        "Xanthine oxidase"
      ],
      "answer": "Inosine monophosphate dehydrogenase (IMPDH)"
    },
    {
      "question": "How is mycophenolate primarily metabolized in the body?",
      "options": [
        "By glucuronidation in the liver",
        "By cytochrome P450 enzymes",
        "By hydrolysis in plasma",
        "By intestinal bacteria"
      ],
      "answer": "By glucuronidation in the liver"
    },
    {
      "question": "Which of the following drugs can reduce the effectiveness of mycophenolate?",
      "options": [
        "Cyclosporine and rifampin",
        "Ketoconazole and fluconazole",
        "Aspirin and ibuprofen",
        "Tacrolimus and sirolimus"
      ],
      "answer": "Cyclosporine and rifampin"
    },
    {
      "question": "What is a serious long-term risk associated with mycophenolate use?",
      "options": [
        "Increased risk of opportunistic infections",
        "Hypotension and bradycardia",
        "Hyperkalemia and weight gain",
        "Liver enzyme induction"
      ],
      "answer": "Increased risk of opportunistic infections"
    },
    {
      "question": "Why is therapeutic drug monitoring important for mycophenolate therapy?",
      "options": [
        "To balance efficacy and minimize toxicity",
        "To prevent acute liver failure",
        "To enhance renal clearance",
        "To reduce dependency on other immunosuppressants"
      ],
      "answer": "To balance efficacy and minimize toxicity"
    },
    {
      "question": "What is a key advantage of mycophenolate over calcineurin inhibitors like cyclosporine?",
      "options": [
        "It does not cause nephrotoxicity",
        "It directly inhibits interleukin-2 production",
        "It enhances kidney function in transplant patients",
        "It does not suppress the immune system"
      ],
      "answer": "It does not cause nephrotoxicity"
    },
    {
      "question": "What is the active form of mycophenolate mofetil after administration?",
      "options": [
        "Mycophenolic acid",
        "Mycophenolate sodium",
        "Mycophenolate glucuronide",
        "Mycophenolate phosphate"
      ],
      "answer": "Mycophenolic acid"
    },
    {
      "question": "Which of the following cells is most affected by mycophenolate due to their reliance on de novo purine synthesis?",
      "options": [
        "Erythrocytes",
        "Neutrophils",
        "Lymphocytes",
        "Platelets"
      ],
      "answer": "Lymphocytes"
    },
    {
      "question": "How does mycophenolate affect the production of guanosine nucleotides?",
      "options": [
        "It promotes the conversion of inosine monophosphate (IMP) to guanosine monophosphate (GMP)",
        "It inhibits the conversion of inosine monophosphate (IMP) to guanosine monophosphate (GMP)",
        "It enhances the salvage pathway for guanosine nucleotides",
        "It increases the production of xanthine oxidase"
      ],
      "answer": "It inhibits the conversion of inosine monophosphate (IMP) to guanosine monophosphate (GMP)"
    }
  ]
}